

SUVEN LIFE SCIENCES LTD

Regd. Off: SDE Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

STATEMENT OF UN-AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th June' 2019

Rs. In Lakhs

	STATEMENT OF UN-AUDITED S	TED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE Q STANDALONE				QUARTER ENDED 30th June' 2019 CONSOLIDATED			
SI.	PARTICULARS -	For the Quarter Ended			For the year Fo		r the Quarter Er		For the year ended
No.		30/06/2019 Un-Audited	31/03/2019 Audited	30/06/2018 Un-Audited	31/03/2019 Audited	30/06/2019 Un-Audited	31/03/2019 Audited	30/06/2018 Un-Audited	31/03/2019 Audited
1	Income								
	Revenue from operations	19,898.63	25,329.94	19,166.22	66,350.44	19,898.63	25,329.93	19,166.22	66,350.44
	Other Income	300.67	375.33	812.77	2,422.93	300.67	375.33	812.77	2,422.93
	Total income	20,199.30	25,705.27	19,978.99	68,773.37	20,199.30	25,705.26	19,978.99	68,773.37
2	Expenses								
	a) Cost of materials	5,866.31	6,235.09	3,859.30	20,413.82	5,866.31	6,235.08	3,859.30	20,413.82
	b) Purchases of stock-in-trad	-	-	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in- progress and stock-in-trade	(1,732.14)	1,302.19	2,595.82	(3,061.41)	(1,732.14)	1,302.19	2,595.82	(3,061.41)
	d) Employee benefits expens	1,875.41	1,739.22	1,714.82	6,347.79	1,942.44	1,809.92	1,775.98	6,612.45
	e) Finance costs	130.75	157.49	106.79	376.31	168.72	157.82	107.04	377.38
	f) Depreciation and amortisation expense	555.03	546.26	550.81	2,214.05	555.03	546.26	550.81	2,214.05
	g) Manufacturing Exps	2,534.68	2,499.40	2,285.50	9,982.32	2,534.68	2,499.40	2,285.50	9,982.32
	h) R & D Exps	1,310.14	1,786.89	1,598.87	6,027.60	4,285.71	4,702.99	2,775.79	11,985.07
	i) Other Expenses	1,040.96	1,237.68	1,288.81	4,286.59	1,057.26	1,257.29	1,332.27	4,375.37
	Total expenses	11,581.14	15,504.22	14,000.72	46,587.07	14,678.01	18,510.95	15,282.51	52,899.05
	Profit before exceptional items & Tax (1-2)	8,618.16	10,201.05	5,978.27	22,186.30	5,521.29	7,194.31	4,696.48	15,874.32
4	Exceptional Items	-	-	-	-	-		-	-
5	Profit before Tax (3-4)	8,618.16	10,201.05	5,978.27	22,186.30	5,521.29	7,194.31	4,696.48	15,874.32
6	Tax Expenses								
	a) Current tax	3,483.61	2,143.99	1,249.14	4,604.23	3,483.61	2,143.99	1,249.14	4,604.23
	b) Deferred tax	(583.22)	1,259.22	844.92	2,575.78	(583.22)	1,259.22	844.92	2,575.78
,	Net Profit/ (Loss) for the period/year(5-6) Other Comprehensive	5,717.77	6,797.84	3,884.21	15,006.29	2,620.90	3,791.10	2,602.42	8,694.31
0	lincome (i) Items that will not be reclassified to profit or loss	(5.29)	10.59	(10.58)	(21.16)	(5.29)	10.59	(10.58)	(21.16)
	(ii) Income tax relating to items that will not be reclassified to profit or	1.85	(3.70)	3.66	7.39	1.85	(3.70)	3.66	7.39
	loss (i) Items that will be reclassified to profit or loss	-	-	-		-			
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-		-		-	-
	Total other Comprehensive Income	(3.44)	6.89	(6.92)	(13.77)	(3.44)	6.89	(6.92)	(13.77)
9	Total Comprehensive Income for the period	5,714.33	6,804.73	3,877.29	14,992.52	2,617.46	3,797.99	2,595.50	8,680.54
10	(7+8) Paid-up equity share capital	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
	Other Equity	103,802.33	84,178.15	89,274.45	98,088.00	84,178.15	81,826.56	78,054.80	81,826.56
12	Earning Per Share (EPS) (Face value of Rs.1/- each)	.55,552.55	51,176.15	J/ Z/T.TJ	,0,000.00	5.,,,,	51,020.00	.0,004.00	51,525.50
	a) Basic	4.49	5.34	3.05	11.79	2.06	2.98	2.04	6.83
	b) Diluted	4.49	5.34	3.05	11.79	2.06	2.98	2.04	6.83
		(not annualised)	(not annualised)	(not annualised)		(not annualised)	(not annualised)	(not annualised)	

	SEGMENT WISE REVENUE, RESULTS AND TOTAL ASSETS AND LIABILITIES STANDALONE CONSOLIDATED								0
	PARTICULARS	For the Quarter Ended			For the year Ended	For the Quarter Ended			For the year Ended
		30/06/2019	31/03/2019	30/06/2018	31/03/2019	30/06/2019	31/03/2019	30/06/2018	31/03/2019
		Un-Audited	Audited	Un-Audited	Audited	Un-Audited	Audited	Un-Audited	Audited
1	SEGMENT REVENUE :-								
	a) Manufacturing (CRAMS)	19,616.35	23,742.62	18,024.22	61,362.91	19,616.35	23,742.62	18,024.22	61,362.91
	b) Services (DDDSS)	282.28	1,587.32	1,142.00	4,987.53	282.28	1,587.32	1,142.00	4,987.53
	c) Research & Development	-	-	-	-	-		-	-
	TOTAL	19,898.63	25,329.94	19,166.22	66,350.44	19,898.63	25,329.94	19,166.22	66,350.44
	Less Inter segment Revenue	=	-	-	-	-	-		
	Net Sales from Operations	19,898.63	25,329.94	19,166.22	66,350.44	19,898.63	25,329.94	19,166.22	66,350.44
2	SEGMENT RESULTS :- Profit/(Loss) before tax and interest:								
	a) Manufacturing (CRAMS)	10,587.58	12,117.59	7,086.74	26,594.91	10,587.57	11,851.99	7,025.59	26,330.25
	b) Services (DDDSS)	60.20	570.44	761.15	2,558.00	60.20	821.14	758.56	2,551.33
	c) Research & Development	(1,310.15)	(1,786.89)	(1,598.88)	(6,027.60)	(4,367.88)	(4,702.99)	(2,775.79)	(11,985.07)
	TOTAL	9,337.63	10,901.14	6,249.01	23,125.31	6,279.89	7,970.14	5,008.36	16,896.51
Less	: i) Interest	46.41	69.59	35.97	199.02	84.05	69.59	35.97	199.02
	ii) Other Un-allocable expenditure/(Income), net	673.06	630.50	234.77	739.99	674.55	706.24	275.91	823.17
	Total Profit Before Tax	8,618.16	10,201.05	5,978.27	22,186.30	5,521.29	7,194.31	4,696.48	15,874.32
3	SEGMENT ASSETS :								
	a) Manufacturing (CRAMS)	72,577.41	69,666.60	48,587.81	69,666.60	71,575.12	69,668.49	48,306.00	69,668.49
	b) Services (DDDSS)	5,629.15	5,687.52	4,339.17	5,687.52	5,604.44	5,687.52	4,329.43	5,687.52
	c) Research & Development	2,918.73	3,022.45	2,784.33	3,022.45	4,055.30	3,022.45	3,094.30	3,022.45
	d) Un allocated	43,436.44	39,125.31	50,187.02	39,125.31	28,605.45	25,510.28	39,450.85	25,510.28
	TOTAL	124,561.73	117,501.88	105,898.33	117,501.88	109,840.31	103,888.74	95,180.58	103,888.74
	SEGMENT LIABILITIES:								
	a) Manufacturing (CRAMS)	11,100.58	9,189.76	9,053.42	9,189.76	8,798.99	9,912.30	8,700.72	9,912.30
	b) Services (DDDSS)	273.05	641.72	315.25	641.72	216.43	688.83	303.33	688.83
	c) Research & Development	1,610.78	1,592.07	1,323.46	1,592.07	9,118.52	3,388.76	2,195.85	3,388.76
	d) Un allocated	1,197.17	829.03	867.09	829.03	950.40	910.98	861.23	910.98
	TOTAL	14,181.58	12,252.58	11,559.22	12,252.58	19,084.34	14,900.87	12,061.13	14,900.87

¹⁾ The above results were reviewed by Audit Committee of the Board and approved by the Board of Directors' at their Meeting held on 14th August, 2019 and the same has been reviewed by the Statutory Auditors.

For SUVEN LIFE SCIENCES LTD

VENKAT JASTI Chairman & CEO DIN: 00278028

Place: Hyderabad Date: 14th Aug' 2019

²⁾ An Investment of USD 35.00 Million, 25% stake, in Rising Holdings Inc, (formerly known as Shore Suven pharma Inc) was made during April 2019, through our wholly owned subsidiary Suven Pharma Inc. The acquisition of Assets and Liabilities are under US court supervised process of Sec 363 of U.S. Bankruptcy code. As the Assets and Liabilities valuation is under process and the business operations are yet to commence, the company did not consider Rising Holdings Inc. for the consolidation.

³⁾ The figures for the Qtr ended 31/03/2019 are the balancing figures in respect of the full financial year and unaudited published year to date figures up to the third Qtr of the relevant financial year.

⁴⁾ The corresponding previous period figures have been regrouped / reclassified where ever necessary.